skip to primary navigationskip to content


London Bioscience Innovation Centre or Babraham Research Campus, Cambridge Permanent

Cancer Research Technology (CRT), a wholly owned subsidiary of Cancer Research UK, is a vibrant drug discovery and commercialisation company which aims to advance new discoveries to beat cancer. To help achieve this goal CRT has its own drug discovery laboratories, CRT Discovery Laboratories (CRTDL), based at locations in Central London and Cambridge. 

CRTDL is dedicated to helping cancer patients through establishing and prosecuting theme-based alliances with industry. We collaborate with the academic community and our commercial partners to discover and develop novel cancer therapies. Our pioneering model has already resulted in cancer drug discovery alliances with major international partners including AstraZeneca, Forma Therapeutics and Teva Pharmaceuticals. 

Laboratory-based positions at senior scientist / scientist levels (grade dependent on experience) have become available within CRTDL’s Discovery Bioscience immuno-oncology team. Key roles will include performing target validation and disease positioning studies and also supporting cell-based assay development and compound profiling in the fast-emerging field of immuno-oncology. Knowledge of immunology and oncology targets and pathways, and an ability to appraise their potential from a translational perspective is essential. The successful candidates will be experts in the use of cell culture and will be able to demonstrate a broad range of techniques applicable to target validation and development of cell-based assays, including the use of technologies for the modulation of target expression/activity, detection of gene/protein expression, and phenotypic evaluation. The successful applicants will form an integral part of the CRTDL team working alongside our industry partners to progress novel cancer targets towards patient benefit. 

The scientist role would suit an individual with PhD level qualifications with laboratory experience in immunology and oncology. Previous experience in translational research, and/or knowledge of the drug discovery process would be an advantage. The senior scientist position would suit a scientist with a recent PhD and relevant postdoctoral experience (or equivalent experience) in oncology or immunology research, ideally gained in a biotechnology or pharmaceutical company. 

Both roles require a strong team player with excellent communication skills who are able to interact with multi-disciplinary project and research leadership teams both internally and externally with our industry and academic collaborators. Strong organisation skills are required to independently and collaboratively deliver on specific project goals and deadlines. 

The positions will be based either at our Cambridgeshire Site on the Babraham Research Campus or London laboratory at the London Bioscience Innovation centre (LBIC).

How to Apply

To apply, simply click the link below to Cancer Research UK's career website where you can submit your application.

Upcoming events


Apr 05, 2019

Trinity College Dublin

Upcoming events

The new Capella building- CITIID

See the home of CITIID being built in this fantastic time-lapse video. From basement to water tight in 17 months. The Capella building will be finished in 2018.


‘Fibroblast’ has been developed from a conversation between Harold Offeh and Dr Alice Denton, a scientist based at the Babraham Institute and a member of the Cambridge Immunology Network. Offeh was particularly interested in the character and roles played by particular cells in the immune system, as well as the immune system’s role as a primary source of protection and care. The film takes as a starting point microscopic images of broblast cells, an area of research for Dr Denton.

FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities

Read more